Foster BJ - Search Results

1

Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.

Foster BJ, LoRusso PM, Poplin E, Zalupski M, Valdivieso M, Wozniak A, Flaherty L, Kasunic DA, Earhart RH, Baker LH. Foster BJ, et al. Invest New Drugs. 1996;13(4):321-6. doi: 10.1007/BF00873138. Invest New Drugs. 1996. PMID: 8824350 Clinical Trial.

2

Preclinical antitumor activity of CI-994.

LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR 3rd, Corbett TH. LoRusso PM, et al. Invest New Drugs. 1996;14(4):349-56. doi: 10.1007/BF00180810. Invest New Drugs. 1996. PMID: 9157069

3

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L. LoRusso P, et al. Among authors: foster bj. Clin Cancer Res. 1995 Dec;1(12):1487-93. Clin Cancer Res. 1995. PMID: 9815948 Clinical Trial.

4

Chronic oral administration of CI-994: a phase 1 study.

Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM. Prakash S, et al. Among authors: foster bj. Invest New Drugs. 2001;19(1):1-11. doi: 10.1023/a:1006489328324. Invest New Drugs. 2001. PMID: 11291827 Clinical Trial.

5

Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).

Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH. Foster BJ, et al. Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398. Invest New Drugs. 1997. PMID: 9387041

6

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

7

Phase I pharmacokinetic study of the novel antitumor agent SR233377.

LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. LoRusso PM, et al. Among authors: foster bj. Clin Cancer Res. 2000 Aug;6(8):3088-94. Clin Cancer Res. 2000. PMID: 10955788 Clinical Trial.

8

Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.

Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Foster BJ, et al. Clin Cancer Res. 1997 Nov;3(11):2047-53. Clin Cancer Res. 1997. PMID: 9815596

9

Preclinical anticancer activity of cryptophycin-8.

Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand RA, Lisow L, Golakoti T, Heltzel CE, Ogino J, Patterson GM, Moore RE. Corbett TH, et al. J Exp Ther Oncol. 1996 Mar;1(2):95-108. J Exp Ther Oncol. 1996. PMID: 9414393

10

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140).

Palomino E, Foster B, Kempff M, Corbett T, Wiegand R, Horwitz J, Baker L. Palomino E, et al. Cancer Chemother Pharmacol. 1996;38(5):453-8. doi: 10.1007/s002800050510. Cancer Chemother Pharmacol. 1996. PMID: 8765439

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page